Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 1123
interventional 942
Observational 165
Registry 16

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 441
Drug|placebo 293
Biological|placebo 36
Biological 33
Device 20
Other 20
Behavioral 9
Device|Drug 9
Dietary Supplement 9
Procedure 9
Drug|Other 8
Biological|Drug 6
Biological|Drug|placebo 5
Diagnostic Test 5
Drug|Procedure 5
Drug|Other|placebo 4
Behavioral|Drug 3
Dietary Supplement|placebo 3
Other|Procedure 3
Radiation 3
Behavioral|Other 2
Combination Product 2
Other|placebo 2
placebo 2
Behavioral|Drug|Other 1
Biological|Device|Other 1
Biological|Drug|Radiation 1
Device|Drug|Other 1
Device|Other 1
Device|placebo 1
Dietary Supplement|Drug|placebo 1
Drug|Radiation 1
Other|Radiation 1
Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 293
NA 93
Germany 55
United States|Canada 42
Japan 35
France 33
Canada 32
China 23
United Kingdom 18
Denmark 9
Italy 9
Australia 8
Austria 8
Taiwan 7
Belgium 6
India 6
Egypt 5
Korea, Republic of 5
Mexico 5
Russian Federation 5
Switzerland 5
Brazil 4
Israel 4
Netherlands 4
Norway 4
France|Germany 3
Germany|United Kingdom 3
Ireland 3
New Zealand 3
Spain 3
United States|Canada|Germany 3
United States|Canada|Poland 3
Australia|New Zealand 2
Austria|Germany 2
Canada|France|United Kingdom 2
China|Korea, Republic of|Taiwan 2
Czechia|Germany 2
Turkey 2
United States|Australia|Canada|Moldova, Republic of 2
United States|Canada|Estonia|France|Germany 2
United States|France|Germany|Iceland|Israel|Japan|Norway 2
United States|Germany 2
United States|Panama 2
United States|Puerto Rico 2
United States|United Kingdom 2
Argentina|Austria|Belgium|Bosnia and Herzegovina|Bulgaria|Chile|Colombia|Croatia|Czechia|Denmark|France|Germany|Hong Kong|Hungary|Israel|Korea, Republic of|Netherlands|Poland|Russian Federation|Singapore|Slovakia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Argentina|Austria|Belgium|Czech Republic|Germany|Greece|Hungary|Italy|Korea, Republic of|Mexico|Spain|Taiwan|Thailand 1
Argentina|Bulgaria|Canada|Czechia|Denmark|Estonia|Finland|Germany|Hungary|Norway|Poland|Romania|Spain|Sweden|Switzerland|United Kingdom 1
Australia|Canada|Hungary 1
Australia|Canada|Mexico 1
Australia|Canada|New Zealand 1
Austria|Belgium|Bulgaria|Croatia|Czechia|Denmark|Finland|France|Germany|Greece|Hungary|Israel|Italy|Latvia|Lithuania|Netherlands|Poland|Portugal|Russian Federation|Slovakia|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Belgium|Bulgaria|Czech Republic|Denmark|France|Hungary|Italy|Lithuania|Romania|Russian Federation|Slovakia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
Austria|Belgium|Canada|Denmark|Finland|France|Germany|Greece|Italy|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Belgium|Canada|France|Germany|Hungary|Italy|Netherlands|Poland|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Belgium|Czech Republic|Denmark|Finland|France|Germany|Greece|Hungary|Italy|Netherlands|Norway|Poland|Portugal|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Austria|Belgium|Czech Republic|Denmark|Finland|France|Germany|Greece|Italy|Netherlands|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Austria|Bulgaria|Germany|Hungary|Lithuania|Poland 1
Austria|France|Germany|Hungary|Serbia 1
Austria|Germany|Netherlands|Poland 1
Belgium|Canada|Denmark|Finland|France|Germany|Netherlands|Spain|Sweden|United Kingdom 1
Belgium|Canada|Denmark|France|Sweden 1
Belgium|Canada|Finland|France|Germany|Netherlands|United Kingdom 1
Belgium|Canada|France|Germany|Netherlands|Spain|United Kingdom 1
Belgium|United States|Canada|Germany|Iceland|Latvia|Poland|Russian Federation|Spain|Turkey|United Kingdom 1
Bosnia and Herzegovina|Bulgaria|Canada|Croatia|Israel|Moldova, Republic of|Poland|Romania|Serbia 1
Bulgaria|Czech Republic|Estonia|Germany|Hungary|Poland|Romania|Russian Federation|Slovakia|South Africa|Ukraine|United Kingdom 1
Bulgaria|Czechia|Germany|Greece|Latvia|Poland|Russian Federation 1
Bulgaria|Estonia|Germany|Hungary|Latvia|Poland|Russian Federation|Ukraine 1
Bulgaria|Estonia|Hungary|Poland|Russian Federation|Ukraine 1
Canada|Czechia|Germany 1
Canada|Denmark|France|Germany|United Kingdom 1
Canada|Denmark|France|Norway|Portugal|Spain|Sweden|United Kingdom 1
Canada|Denmark|Germany|Italy|Spain|Sweden 1
Canada|France 1
Canada|Germany 1
Canada|Germany|Ireland|Sweden|United Kingdom 1
Canada|Germany|Poland 1
Canada|Slovakia|Ukraine 1
Canada|United States|Australia|Belgium|Germany|Hungary|Italy|Japan|Poland|Russian Federation|United Kingdom 1
Canada|United States|Australia|Germany|Japan|Latvia|Mexico|Poland 1
Canada|United States|Austria|Belgium|Germany 1
Canada|United States|Belgium|Germany|Poland 1
Chile 1
China|Hungary|Malaysia|Philippines|Thailand|Turkey 1
Croatia|Germany|Poland|Serbia 1
Czech Republic|Hungary 1
Czechia|United States|Australia|Canada|France|Germany|Hungary|Poland|Spain 1
Czechia|United States|Bulgaria|Canada|Estonia|Germany|Latvia|Poland|Slovakia 1
Denmark|Finland|Norway|Sweden 1
Denmark|France|Germany|Italy|Netherlands|Spain|Sweden|United Kingdom 1
Dominican Republic 1
Estonia|Georgia|Poland|Ukraine 1
France|Germany|Greece|Hungary|Italy|Spain|Turkey|United Arab Emirates|United Kingdom 1
France|Germany|Italy|Spain|Switzerland|United Kingdom 1
France|Germany|Italy|Spain|United Kingdom 1
France|Germany|Netherlands|United Kingdom 1
France|Japan|Korea, Republic of|Malaysia|Taiwan|Tunisia 1
France|Spain 1
Germany|Austria|Belgium|France|Hungary|Italy|Netherlands|Poland|Romania|Spain 1
Germany|Austria|Belgium|France|Italy|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Germany|Belgium|Denmark|Finland|France|Greece|Hungary|Italy|Netherlands|Norway|Spain|Sweden 1
Germany|Ireland|Netherlands|Russian Federation|United Kingdom 1
Germany|Israel|Poland|Spain 1
Germany|Poland 1
Greece 1
Hungary 1
Iran, Islamic Republic of 1
Ireland|United Kingdom 1
Italy|Spain 1
Japan|United States|Canada|Czechia|Hungary|Poland 1
Kazakhstan 1
Korea, Republic of|Germany|United States|Australia|Canada|Czechia|Poland|Russian Federation|Spain 1
Korea, Republic of|Taiwan 1
Latvia|United States|Bulgaria 1
Netherlands|Poland|United States|Australia|Belgium|Canada|France|Germany|Spain|Turkey|United Kingdom 1
Pakistan 1
Philippines 1
Poland 1
Poland|Belgium|Bulgaria|Czechia|Estonia|France|Germany|Greece|Israel|Italy|Latvia|Lithuania|Portugal|Romania|Slovakia|Spain|United Kingdom 1
Poland|United States|Canada|Denmark 1
Spain|Sweden|Austria|Belgium|Bulgaria|Denmark|Finland|France|Germany|Greece|Hungary|Israel|Lithuania|Netherlands|Norway|Poland|Portugal|Slovakia|United Kingdom 1
Sweden 1
Switzerland|United States|Austria|Canada|Denmark|France|Germany|Italy|Spain 1
United Kingdom|Belgium|Canada|France|Germany|Hungary|Portugal|Russian Federation|Sweden|Ukraine 1
United States|Argentina|Australia|Belgium|Canada|Colombia|Egypt|Finland|France|Germany|Guatemala|Hungary|Iceland|India|Italy|Korea, Republic of|Philippines|Poland|Romania|Singapore|Spain|Sweden|United Kingdom 1
United States|Argentina|Australia|Belgium|Canada|Colombia|Estonia|Finland|France|Germany|Guatemala|Hungary|Iceland|Israel|Italy|Japan|Korea, Republic of|Latvia|Lithuania|Poland|Romania|Singapore|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Germany|Guatemala|Italy|Turkey|United Kingdom 1
United States|Argentina|Australia|Brazil|Bulgaria|Canada|Denmark|Finland|Greece|Netherlands|Slovakia|United Kingdom 1
United States|Argentina|Australia|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Poland|Puerto Rico|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Japan|Korea, Republic of|Poland|Puerto Rico|Spain|United Kingdom 1
United States|Argentina|Australia|Canada|Czechia|Germany|Hungary|Japan|Korea, Republic of|Mexico|Poland|Puerto Rico|Romania|Taiwan 1
United States|Argentina|Bulgaria|Canada|Chile|Germany|Hungary|Mexico|Poland|Russian Federation 1
United States|Argentina|Canada|Colombia|Estonia|Iceland|Israel|Japan|Latvia|Lithuania|Mexico|Taiwan 1
United States|Argentina|Canada|Czechia|France|Germany|Hungary|Mexico|Netherlands|Poland|Puerto Rico|Russian Federation|Spain 1
United States|Australia 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|Denmark|Estonia|France|Germany|Greece|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Norway|Portugal|Slovakia|Spain|Switzerland|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|Finland|France|Germany|Japan|Korea, Republic of|Mexico|Poland|Portugal|Spain|Sweden|Taiwan 1
United States|Australia|Austria|Belgium|Canada|Netherlands|Puerto Rico|Turkey 1
United States|Australia|Austria|Canada|Czechia|France|Germany|Netherlands|Poland|Romania|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|Estonia|Germany|Hungary|Latvia|Netherlands|United Kingdom 1
United States|Australia|Belgium|Canada|Czechia|France|Germany|Hungary|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|Finland|Hungary|Israel|Netherlands|Norway|Portugal|Russian Federation|Slovakia|Spain|Turkey|United Kingdom 1
United States|Australia|Belgium|Canada|Germany|Hungary|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Taiwan|United Kingdom 1
United States|Australia|Belgium|Canada|Germany|Hungary|Italy|Netherlands|Poland 1
United States|Australia|Belgium|Czechia|Denmark|Germany|Greece|Spain|United Kingdom 1
United States|Australia|Bulgaria|Canada 1
United States|Australia|Bulgaria|Canada|Denmark|Germany|Hungary|Japan|Latvia|Poland 1
United States|Australia|Canada|Czechia|Finland|France|Germany|Hungary|Israel|Italy|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1
United States|Australia|Canada|Denmark|Germany|Hungary|Italy|Japan|Poland|Romania|United Kingdom 1
United States|Australia|Canada|Germany|Hungary|Korea, Republic of|Poland|Russian Federation|Spain|Taiwan 1
United States|Australia|Canada|Germany|Hungary|Korea, Republic of|Poland|Russian Federation|Taiwan 1
United States|Australia|Canada|Germany|Hungary|Korea, Republic of|Poland|Russian Federation|United Kingdom 1
United States|Australia|Canada|Germany|Israel|Poland|South Africa 1
United States|Australia|Canada|Germany|Korea, Republic of|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|China 1
United States|Australia|Germany|Israel|Italy|Spain|Taiwan|United Kingdom 1
United States|Australia|New Zealand 1
United States|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Greece|Italy|Spain|Sweden|Switzerland|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Poland|Puerto Rico|Spain|Switzerland 1
United States|Austria|Bulgaria|Canada|Czech Republic|France|Germany|India|Italy|Japan|Poland|Singapore|Slovakia|Switzerland|United Kingdom|Vietnam 1
United States|Austria|Bulgaria|Canada|Czechia|France|Germany|Italy|Japan|Poland|Singapore|Slovakia|Switzerland|United Kingdom|Vietnam 1
United States|Austria|Canada|Denmark|France|Germany|Netherlands|Switzerland|United Kingdom 1
United States|Austria|Canada|France|Germany|India|Japan|Slovakia 1
United States|Austria|Canada|France|Germany|Switzerland|United Kingdom 1
United States|Austria|Canada|Poland 1
United States|Austria|Germany|Poland 1
United States|Belgium|Bulgaria|Canada|Czechia|Estonia|France|Japan|Mexico|Netherlands|Poland|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Belgium|Canada 1
United States|Belgium|Canada|Czechia|France|Germany|Israel|Italy|Netherlands|Russian Federation|Spain 1
United States|Belgium|Canada|Denmark|France|Germany|Hungary 1
United States|Belgium|Canada|Denmark|France|Germany|Netherlands|Spain|United Kingdom 1
United States|Belgium|Canada|France|Germany|Italy|Puerto Rico 1
United States|Belgium|Canada|Germany|Hungary|Italy|Spain 1
United States|Belgium|Canada|Germany|Hungary|Korea, Republic of|Netherlands|Poland|Taiwan 1
United States|Belgium|Canada|Germany|Italy 1
United States|Belgium|Colombia|Egypt|Estonia|France|Germany|Guatemala|Hungary|Israel|Italy|Japan|Latvia|Poland|Romania|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Belgium|Czechia|Estonia|Germany|Peru|Poland|Russian Federation|Spain 1
United States|Bulgaria|Canada|Chile|Croatia|Estonia|Georgia|Israel|Italy|Latvia|Moldova, Republic of|Poland|Russian Federation|Slovakia|South Africa|Ukraine 1
United States|Bulgaria|Canada|Czechia|Estonia|France|Germany|Hungary|Mexico|Poland|Russian Federation|United Kingdom 1
United States|Bulgaria|Canada|Czechia|Germany|Hungary|Poland 1
United States|Bulgaria|Czechia|France|Germany|Hungary|Netherlands|Poland|United Kingdom 1
United States|Bulgaria|France|Slovakia 1
United States|Bulgaria|Israel|Romania 1
United States|Bulgaria|Poland|United Kingdom 1
United States|Canada|China|Germany|Japan|Korea, Republic of|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Canada|Colombia|Germany|Hungary|Japan|Mexico|Poland|Serbia|Taiwan|Ukraine 1
United States|Canada|Colombia|Germany|Hungary|Mexico|Poland|Puerto Rico|Serbia|Taiwan|Ukraine 1
United States|Canada|Czechia|Germany|Hungary 1
United States|Canada|Czechia|Germany|Hungary|Italy|Russian Federation 1
United States|Canada|Czechia|Guatemala|Hungary|Iceland|Korea, Republic of|Malaysia|Poland|Slovakia|Vietnam 1
United States|Canada|Czechia|Hungary|Japan|Poland 1
United States|Canada|Estonia|Iceland|Japan|Latvia 1
United States|Canada|Finland|France|Germany|Norway|Sweden 1
United States|Canada|France|Germany|Italy|Netherlands|Poland|Spain|United Kingdom 1
United States|Canada|France|Germany|Poland|Romania|United Kingdom 1
United States|Canada|France|Germany|Poland|United Kingdom 1
United States|Canada|Germany|Iceland|Poland|Spain 1
United States|Canada|Germany|Japan|Poland|Puerto Rico 1
United States|Canada|Germany|Spain 1
United States|Canada|Germany|United Kingdom 1
United States|Canada|Hong Kong|South Africa 1
United States|Canada|Hungary|Japan|Poland 1
United States|Canada|Japan 1
United States|Canada|Japan|Poland 1
United States|Canada|Japan|Puerto Rico 1
United States|Canada|Puerto Rico 1
United States|Canada|Spain 1
United States|China|France|Germany|Japan|Korea, Republic of|Malaysia|Singapore|Switzerland|Taiwan|Thailand|Tunisia 1
United States|Czechia|Estonia|Germany|Poland|Russian Federation|Slovakia|Ukraine 1
United States|Denmark 1
United States|France|Germany|Malaysia|Singapore|Taiwan|Thailand 1
United States|France|Korea, Republic of|Spain 1
United States|Georgia|Poland|Ukraine 1
United States|Georgia|Ukraine 1
United States|Germany|Hungary|Latvia|Poland|Russian Federation|Ukraine 1
United States|Germany|Israel 1
United States|Germany|Japan|Korea, Republic of|Mexico|Poland|Puerto Rico|Russian Federation|Taiwan 1
United States|Germany|United Kingdom 1
United States|Netherlands|Poland|Romania 1
United States|Poland 1
United States|Switzerland|United Kingdom 1

Sites per Study

Site_count Study_Count
1 425
2 41
3 38
4 26
5 22
6 15
7 20
8 17
9 16
10 16
11 12
12 12
13 9
14 9
15 10
16 11
17 8
18 7
19 7
20 5
21 4
22 5
23 5
24 3
25 2
26 6
27 5
28 5
29 1
30 8
31 10
32 5
33 6
34 9
35 4
36 4
37 2
38 2
39 7
40 7
41 2
42 1
43 5
44 2
45 6
46 5
47 1
48 2
49 3
50 3
52 2
53 1
54 4
56 1
57 1
58 2
59 1
60 1
62 2
64 3
67 1
68 3
69 2
70 1
73 1
74 3
76 3
77 4
78 1
79 2
82 1
85 1
87 3
88 1
89 1
90 1
94 3
96 1
98 1
99 1
100 1
101 2
102 1
104 2
105 1
109 2
111 1
116 2
118 1
122 1
124 1
125 1
127 1
130 1
131 1
137 1
142 1
152 2
155 1
165 1
178 1
182 1
189 1
200 1
205 1
215 1
232 1
233 1

Phase

Phase Study_Count
Phase 2 259
Phase 3 259
Phase 4 148
Phase 1 139
N/A 94
Phase 1/Phase 2 27
Phase 2/Phase 3 12
Early Phase 1 4

Number of Arms

Number_of_Arms Count_of_Studies
1 204
2 359
3 121
4 81
5 40
6 34
7 9
8 14
9 1
10 1
13 1
14 2
NA 75

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 8 4.0000 6.0000 5.00000 3.0000 31.00 0.0000 6.0000
1st Qu. 20 20.0000 20.5000 9.50000 30.0000 42.75 160.0000 30.0000
Median 32 47.0000 35.0000 20.00000 64.0000 93.00 327.0000 66.5000
Mean 35 101.3656 55.3741 35.59259 105.7471 104.50 512.5875 163.6301
3rd Qu. 47 110.0000 59.5000 38.00000 150.0000 141.75 642.0000 151.5000
Max. 68 1050.0000 699.0000 194.00000 617.0000 293.00 16487.0000 1852.0000

Trial Group Type

group_type Group_Count
Experimental 1304
Placebo Comparator 418
Active Comparator 413
Other 83
NA 75
No Intervention 22
Sham Comparator 8

Intervention Model

intervention_model Study_Count
Parallel Assignment 611
Single Group Assignment 258
Crossover Assignment 31
NA 18
Sequential Assignment 14
Factorial Assignment 10

Primary Purpose

primary_purpose Study_Count
Treatment 830
Basic Science 33
Other 28
NA 20
Supportive Care 12
Prevention 7
Diagnostic 6
Health Services Research 4
Educational/Counseling/Training 1
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 36
NA 27
Germany 16
Canada 8
France 6
Turkey 6
Spain 5
Italy 4
United Kingdom 4
Austria 3
Denmark 3
Greece 3
Japan 3
Korea, Republic of 3
Belgium 2
China 2
Netherlands 2
Russian Federation 2
Argentina|Australia|Austria|Canada|France|Germany|Hungary|Japan|Netherlands|Switzerland|United Arab Emirates|United Kingdom 1
Australia 1
Austria|Belgium|Denmark|France|Germany|Netherlands|Norway|Russian Federation|Switzerland|United Kingdom 1
Austria|Germany|Ireland|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Germany|Italy|Netherlands 1
Belgium|Canada|Czechia|Germany|United Kingdom 1
Brazil 1
Canada|Sweden|United Kingdom 1
Colombia 1
Czech Republic|Estonia|Hungary|Israel|Romania|Slovakia|Slovenia|Ukraine 1
Denmark|Germany|Poland|Spain|United Kingdom 1
France|Germany|Greece|Hungary|Italy|Netherlands|Portugal|Spain 1
Hong Kong 1
Hungary 1
Indonesia|Korea, Republic of|Malaysia|Singapore|Taiwan 1
Israel|Netherlands|Austria|Belgium|France|Greece|Ireland|Norway|Russian Federation|South Africa|Spain|United Kingdom 1
Kazakhstan 1
Poland 1
Portugal 1
Romania 1
Sweden 1
Switzerland 1
Taiwan 1
United States|Argentina|Australia|Austria|Belgium|Canada|Chile|Colombia|Czechia|Greece|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Portugal|Slovakia|Slovenia|Spain|Sweden|Taiwan|Ukraine 1
United States|Argentina|Austria|Belgium|Canada|Denmark|Finland|France|Germany|Hungary|Ireland|Israel|Netherlands|Norway|Poland|Spain|Sweden|Switzerland|United Kingdom 1
United States|Austria|Canada|Czechia|Denmark|France|Germany|Greece|Ireland|Netherlands|Puerto Rico|Spain|Sweden|United Kingdom 1
United States|Belgium|Canada|France|Germany|Netherlands 1
United States|Canada 1
United States|Canada|Chile|Hong Kong|Italy|Netherlands 1
United States|France|Germany|Italy|United Kingdom 1

Sites per Study

Site_count Study_Count
1 108
2 3
3 1
4 1
5 2
6 1
7 1
8 1
9 5
10 2
11 1
12 3
14 1
15 2
16 3
19 1
21 1
22 2
24 1
25 1
29 1
30 3
32 1
34 1
36 1
43 1
48 1
61 1
73 1
77 1
96 1
106 1
120 2
147 1
180 1
182 1
212 1
313 1
432 1
634 1
641 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 60.0000
Median 168.0000
Mean 791.2883
3rd Qu 601.5000
Max 20000.0000

Observation Model

observational_model Study_Count
Cohort 86
Case-Only 23
Case-Control 18
NA 13
Other 12
Case Control 11
Defined Population, Natural History 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 123
Cross-Sectional 16
Retrospective 12
NA 9
Other 3
Cross-Sectional, Retrospective/Prospective 1
Longitudinal, Retrospective 1

Registries

Studies by Country

Country Study_Count
NA 5
United States 4
Germany 3
Argentina|Brazil|Canada|Costa Rica|Dominican Republic|Guatemala|Mexico 1
Italy 1
Spain 1
Sweden 1

Sites per Study

Site_count Study_Count
1 13
13 1
38 1
79 1

Enrollment Metrics

Measure Registries
Min 24.00
1st Qu 215.00
Median 3005.50
Mean 57796.19
3rd Qu 10000.00
Max 700000.00

Registry Model

observational_model Study_Count
Cohort 13
Case-Only 1
Case Control 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 10
Other 4
Cross-Sectional 2

Follow-up

target_duration Study_Count
5 Years 3
1 Day 2
2 Years 2
8 Years 2
1 Year 1
10 Years 1
14 Years 1
30 Years 1
6 Months 1
60 Months 1
8 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03399708 Immune Metabolic Associations in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03399708 Completed NHS Greater Glasgow and Clyde 2019-10-12
NCT03284879 Post-Marketing Surveillance Study of OTEZLA https://ClinicalTrials.gov/show/NCT03284879 Recruiting Amgen 2021-08-31
NCT04439526 A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis https://ClinicalTrials.gov/show/NCT04439526 Recruiting Janssen-Cilag S.p.A. 2023-06-30
NCT04316533 Work Stress and Impact of Pruritus on Quality of Life https://ClinicalTrials.gov/show/NCT04316533 Completed University Hospital, Brest 2020-06-30
NCT03402828 Body PSOriasis: Long-term Relapse CONTROL https://ClinicalTrials.gov/show/NCT03402828 Active, not recruiting LEO Pharma 2020-07-01
NCT03361215 Disease Trajectories in Atopic Dermatitis and Psoriasis https://ClinicalTrials.gov/show/NCT03361215 Recruiting University of Schleswig-Holstein 2027-01-01
NCT03358914 The PsoTeenQOL - Preliminary Reliability and Validity https://ClinicalTrials.gov/show/NCT03358914 Completed University of Aarhus 2019-01-15
NCT03339089 Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases https://ClinicalTrials.gov/show/NCT03339089 Recruiting AbbVie 2021-06-30
NCT03223012 Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn’s Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service https://ClinicalTrials.gov/show/NCT03223012 Completed AbbVie 2019-02-28
NCT03198390 Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions https://ClinicalTrials.gov/show/NCT03198390 Recruiting University of Arizona 2020-07-01
NCT03099083 Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab https://ClinicalTrials.gov/show/NCT03099083 Completed AbbVie 2019-04-05
NCT02978001 Insulin Sensitivity, Glucose - and Fat Metabolism in Patients With Psoriasis https://ClinicalTrials.gov/show/NCT02978001 Completed University Hospital, Gentofte, Copenhagen 2019-01-01
NCT02954081 APremilast After FumaRic Acid Ester Treatment https://ClinicalTrials.gov/show/NCT02954081 Recruiting Amgen 2022-05-27
NCT02935582 PSOREAL - Managing PSOriasis in the REAL World https://ClinicalTrials.gov/show/NCT02935582 Recruiting LEO Pharma 2023-12-31
NCT02910791 The Role of Bacterial Toxins in Human Skin Disease https://ClinicalTrials.gov/show/NCT02910791 Recruiting National Jewish Health 2022-12-31
NCT02899429 Ultrasound Study of Entheses and Small Joints of Hands and Feet in Patients With Atypical Form of Psoriasis https://ClinicalTrials.gov/show/NCT02899429 Completed University Hospital, Brest 2015-12-31
NCT02881346 Efficacy and Tolerability of Enstilar® in Daily Practice https://ClinicalTrials.gov/show/NCT02881346 Completed LEO Pharma 2017-03-31
NCT02856542 Real-life Evaluation of the Daivobet® Gel Applicator https://ClinicalTrials.gov/show/NCT02856542 Completed LEO Pharma 2017-06-30
NCT03218488 A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis https://ClinicalTrials.gov/show/NCT03218488 Recruiting Janssen-Cilag International NV 2026-09-15
NCT02796014 Assessment of Dermatologic Family Impact Scale in the Parents of Children With Psoriasis https://ClinicalTrials.gov/show/NCT02796014 Completed Istanbul Medeniyet University 2017-03-31
NCT02752672 Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis https://ClinicalTrials.gov/show/NCT02752672 Completed Medical University of Graz 2016-11-30
NCT02750800 Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie’s Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE) https://ClinicalTrials.gov/show/NCT02750800 Completed AbbVie 2018-04-03
NCT02740218 A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice https://ClinicalTrials.gov/show/NCT02740218 Recruiting Amgen 2021-04-30
NCT02713295 A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece https://ClinicalTrials.gov/show/NCT02713295 Completed AbbVie 2019-04-19
NCT02668341 Cross Sectional Analysis of Healthcare for Psoriasis in 5 European Countries https://ClinicalTrials.gov/show/NCT02668341 Enrolling by invitation Universitätsklinikum Hamburg-Eppendorf 2020-09-30
NCT02652494 Observational Study of Apremilast in Patients With Psoriasis in The Netherlands https://ClinicalTrials.gov/show/NCT02652494 Active, not recruiting Amgen 2019-12-31
NCT02636101 Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study https://ClinicalTrials.gov/show/NCT02636101 Completed LEO Pharma 2018-02-15
NCT02626793 A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions https://ClinicalTrials.gov/show/NCT02626793 Completed Amgen 2017-06-08
NCT02570750 The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis https://ClinicalTrials.gov/show/NCT02570750 Completed Pfizer 2016-12-05
NCT00508547 Psoriasis Longitudinal Assessment and Registry (PSOLAR) https://ClinicalTrials.gov/show/NCT00508547 Recruiting Janssen Scientific Affairs, LLC 2021-05-31
NCT02503059 Etanercept Survival in Elderly Population https://ClinicalTrials.gov/show/NCT02503059 Completed Andalusian Network for Design and Translation of Advanced Therapies 2015-01-31
NCT02486302 A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis. https://ClinicalTrials.gov/show/NCT02486302 Completed Pfizer 2017-12-11
NCT02451839 An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY) https://ClinicalTrials.gov/show/NCT02451839 Completed AbbVie 2017-12-05
NCT02417792 The Association Between Psoriasis and Intestinal Bacterial Population https://ClinicalTrials.gov/show/NCT02417792 Completed Assuta Hospital Systems 2019-01-06
NCT02413801 Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients https://ClinicalTrials.gov/show/NCT02413801 Active, not recruiting University of Rochester 2020-12-31
NCT02376478 On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection https://ClinicalTrials.gov/show/NCT02376478 Completed Medical University of Vienna 2011-01-31
NCT02330380 Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation https://ClinicalTrials.gov/show/NCT02330380 Completed University Hospitals Cleveland Medical Center 2016-12-31
NCT02322580 An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients https://ClinicalTrials.gov/show/NCT02322580 Completed Universitaire Ziekenhuizen Leuven 2016-09-30
NCT02305953 Cytokines and Vascular Inflammation in Psoriasis https://ClinicalTrials.gov/show/NCT02305953 Completed Innovaderm Research Inc. 2014-10-31
NCT02274363 A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis https://ClinicalTrials.gov/show/NCT02274363 Completed Janssen Pharmaceutica 2013-05-31
NCT02239666 Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis https://ClinicalTrials.gov/show/NCT02239666 Completed AstraZeneca 2017-01-05
NCT02192164 Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis https://ClinicalTrials.gov/show/NCT02192164 Completed Pfizer 2016-05-31
NCT02193919 A Single-Center, Prospective, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy https://ClinicalTrials.gov/show/NCT02193919 Completed Bagel, Jerry, M.D. 2008-05-31
NCT02174367 An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis https://ClinicalTrials.gov/show/NCT02174367 Active, not recruiting King’s College London 2017-07-31
NCT02162472 Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis https://ClinicalTrials.gov/show/NCT02162472 Recruiting Northwestern University 2020-12-31
NCT02155192 An Exploratory Genetic Study in Participants With Psoriasis https://ClinicalTrials.gov/show/NCT02155192 Completed Janssen Research & Development, LLC 2014-09-30
NCT02078297 IL-17 Role in Variants of Psoriasis https://ClinicalTrials.gov/show/NCT02078297 Completed Innovaderm Research Inc. 2015-02-28
NCT01316224 Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment https://ClinicalTrials.gov/show/NCT01316224 Completed AbbVie 2014-04-30
NCT03358693 Anti-cytokine Signatures in Inflammatory Skin Disease https://ClinicalTrials.gov/show/NCT03358693 Recruiting University of Schleswig-Holstein 2024-12-31
NCT03236870 A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China https://ClinicalTrials.gov/show/NCT03236870 Active, not recruiting AbbVie 2020-09-30
NCT01982552 An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life https://ClinicalTrials.gov/show/NCT01982552 Completed LEO Pharma 2014-01-31
NCT01964443 Clinical Assessment and Psychosocial Impact of Psoriasis https://ClinicalTrials.gov/show/NCT01964443 Completed Janssen Pharmaceutica N.V., Belgium 2015-11-30
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01812954 Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis https://ClinicalTrials.gov/show/NCT01812954 Completed Technische Universität Dresden 2014-06-30
NCT01797224 OTIS Autoimmune Diseases in Pregnancy Project https://ClinicalTrials.gov/show/NCT01797224 Recruiting University of California, San Diego 2020-01-31
NCT01780857 Immune Signature of Palmoplantar Pustulosis https://ClinicalTrials.gov/show/NCT01780857 Completed Baylor Research Institute 2014-07-31
NCT01778569 The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI) https://ClinicalTrials.gov/show/NCT01778569 Recruiting National Institutes of Health Clinical Center (CC) 2030-06-30
NCT01768858 Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn’s Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT01768858 Completed AbbVie 2017-08-13
NCT01707368 Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation https://ClinicalTrials.gov/show/NCT01707368 Completed LEO Pharma 2014-05-31
NCT01706692 Swiss Dermatology Network of Targeted Therapies (SDNTT) https://ClinicalTrials.gov/show/NCT01706692 Recruiting Swiss Dermatology Network for Targeted Therapies 2021-06-30
NCT01677598 A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries https://ClinicalTrials.gov/show/NCT01677598 Completed Johnson & Johnson Pte Ltd 2013-11-30
NCT01623752 Prospective Evaluation of the Radiographic Efficacy of Enbrel https://ClinicalTrials.gov/show/NCT01623752 Completed Pfizer 2018-03-31
NCT01617018 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis https://ClinicalTrials.gov/show/NCT01617018 Recruiting Assistance Publique - Hôpitaux de Paris 2020-07-31
NCT01557283 An Observational Study of the Real Life Management of the Psoriasis Patients Treated With Enbrel According to the New Reimbursement Criteria https://ClinicalTrials.gov/show/NCT01557283 Completed Pfizer 2013-06-30
NCT01555606 An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis https://ClinicalTrials.gov/show/NCT01555606 Completed Janssen Biotech, Inc. 2012-07-31
NCT01465061 A Survey on the Role and Benefits of Online Social Networks on Filipino Patients With Psoriasis https://ClinicalTrials.gov/show/NCT01465061 Completed University of the Philippines 2011-06-30
NCT01425138 Systematic Review And Meta-Analysis Of Psoriasis Treatments. https://ClinicalTrials.gov/show/NCT01425138 Completed Pfizer 2011-06-30
NCT01387815 Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis https://ClinicalTrials.gov/show/NCT01387815 Completed AbbVie 2018-06-29
NCT01401452 Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities https://ClinicalTrials.gov/show/NCT01401452 Completed AbbVie 2016-05-31
NCT01356758 Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents https://ClinicalTrials.gov/show/NCT01356758 Completed University of Aarhus 2015-09-30
NCT01328366 Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab https://ClinicalTrials.gov/show/NCT01328366 Completed AbbVie 2014-05-31
NCT01320774 Efficacy, Tolerability and Handling of Daivobet® Gel in Patients With Psoriasis Vulgaris https://ClinicalTrials.gov/show/NCT01320774 Completed LEO Pharma 2012-01-31
NCT04380597 Observational Study in Patients With Nail Psoriasis Treated With Enstilar® to Assess the Severity Change and the Quality of Life https://ClinicalTrials.gov/show/NCT04380597 Active, not recruiting Complejo Hospitalario Universitario de Pontevedra 2019-12-15
NCT04277832 Evaluating of New Screening Tool for Arthritis* in Psoriasis https://ClinicalTrials.gov/show/NCT04277832 Recruiting Bezmialem Vakif University 2020-08-31
NCT04209894 A Clinical Study of Sub-clinical Enthesitis in Patients With Psoriasis and Healthy Controls https://ClinicalTrials.gov/show/NCT04209894 Active, not recruiting Fatih Sultan Mehmet Training and Research Hospital 2020-11-15
NCT04203693 Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT04203693 Recruiting Almirall, S.A. 2023-07-31
NCT04190758 GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden https://ClinicalTrials.gov/show/NCT04190758 Recruiting Vastra Gotaland Region 2039-12-31
NCT04168619 MTX-related Liver Toxicity in Psoriasis Patients, Using Ultrasound-based Techniques as a Diagnostic Tool https://ClinicalTrials.gov/show/NCT04168619 Recruiting The University of Hong Kong 2020-12-31
NCT04095130 Tissue Sodium in Patients With Psoriasis https://ClinicalTrials.gov/show/NCT04095130 Completed Charite University, Berlin, Germany 2018-03-16
NCT04099979 A Pilot Study to Explore the Role of Gut Flora in Psoriasis https://ClinicalTrials.gov/show/NCT04099979 Recruiting ProgenaBiome 2023-03-31
NCT04053881 A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice https://ClinicalTrials.gov/show/NCT04053881 Recruiting UCB Pharma 2022-04-30
NCT04031027 A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice https://ClinicalTrials.gov/show/NCT04031027 Recruiting Amgen 2020-07-30
NCT04013867 Identification of the Best Self-questionnaire to Diagnose Depression in Patients With Psoriasis (DePsoVal) https://ClinicalTrials.gov/show/NCT04013867 Recruiting University Hospital, Clermont-Ferrand 2019-11-16
NCT03982394 Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis https://ClinicalTrials.gov/show/NCT03982394 Recruiting AbbVie 2025-06-30
NCT03964168 An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers https://ClinicalTrials.gov/show/NCT03964168 Completed Psoriasis Treatment Center of Central New Jersey 2020-03-03
NCT03955861 Ultrasound Enthesitis Response in Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT03955861 Recruiting Belfast Health and Social Care Trust 2020-02-29
NCT03925441 Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea https://ClinicalTrials.gov/show/NCT03925441 Completed AbbVie 2019-08-06
NCT03885089 Infliximab Biosimilar for Intravenous Drip Infusion 100 mg “Pfizer” Drug Use Investigation (Psoriasis) https://ClinicalTrials.gov/show/NCT03885089 Recruiting Pfizer 2023-03-13
NCT03828643 Secukinumab Efficacy Without the Initial Loading Dose in Patients With Psoriasis https://ClinicalTrials.gov/show/NCT03828643 Completed Universita di Verona 2019-04-12
NCT03831646 Clinical, Psychological and Genetic Characteristics in Dermatological Patients https://ClinicalTrials.gov/show/NCT03831646 Completed Astana Medical University 2019-07-10
NCT03816917 Discovery of Arthritis in Psoriasis Patients for Early Rheumatological Referral https://ClinicalTrials.gov/show/NCT03816917 Enrolling by invitation Radboud University 2021-12-01
NCT03807453 Comparison of Scalp Microbiome of the Psoriasis and Seborrheic Dermatitis Patients https://ClinicalTrials.gov/show/NCT03807453 Completed Istanbul Medeniyet University 2019-06-18
NCT03791216 Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment https://ClinicalTrials.gov/show/NCT03791216 Recruiting Northwestern University 2020-12-31
NCT03795402 Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling https://ClinicalTrials.gov/show/NCT03795402 Completed Janssen Research & Development, LLC 2019-11-25
NCT03768284 Genetic Analysis of Pediatric Psoriasis https://ClinicalTrials.gov/show/NCT03768284 Recruiting Northwestern University 2020-10-31
NCT03757364 Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Nail Psoriasis https://ClinicalTrials.gov/show/NCT03757364 Completed University of Warmia and Mazury 2018-09-30
NCT03757013 A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France https://ClinicalTrials.gov/show/NCT03757013 Recruiting Amgen 2021-06-24
NCT03616561 Quality of Life and Ultrasonographic Assessment of Nail Psoriasis After Treatment With Apremilast (JUST Study) https://ClinicalTrials.gov/show/NCT03616561 Active, not recruiting Hospital de Granollers 2020-05-23
NCT03539419 Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain https://ClinicalTrials.gov/show/NCT03539419 Recruiting Amgen 2019-11-02
NCT03492632 Ovarian Reserve in Patients With Psoriasis https://ClinicalTrials.gov/show/NCT03492632 Completed Kanuni Sultan Suleyman Training and Research Hospital 2018-06-30
NCT01262534 A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis. https://ClinicalTrials.gov/show/NCT01262534 Completed Janssen-Cilag, S.A. 2011-06-30
NCT01233583 Regulatory T-cells in Psoriasis Patients as Targets for Therapy https://ClinicalTrials.gov/show/NCT01233583 Completed University of Aberdeen 2013-09-30
NCT01202565 Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT01202565 Completed AbbVie 2013-07-31
NCT01169987 Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life https://ClinicalTrials.gov/show/NCT01169987 Completed AbbVie 2015-03-31
NCT01155570 Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) https://ClinicalTrials.gov/show/NCT01155570 Completed AbbVie 2012-07-31
NCT01139918 Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT01139918 Completed Innovaderm Research Inc. 2014-07-31
NCT01126619 A Study of Effectiveness and Safety of Tumor Necrosis Factor (TNF) Inhibitors in Patients With Moderate to Severe Psoriasis https://ClinicalTrials.gov/show/NCT01126619 Completed Abbott 2011-09-30
NCT01100034 Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis https://ClinicalTrials.gov/show/NCT01100034 Completed Pfizer 2018-09-24
NCT01084668 Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs https://ClinicalTrials.gov/show/NCT01084668 Completed Abbott 2011-04-30
NCT01083121 Surveillance of Humira Injection in Korean Patients https://ClinicalTrials.gov/show/NCT01083121 Completed AbbVie 2012-06-30
NCT01081730 Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database https://ClinicalTrials.gov/show/NCT01081730 Completed Janssen Biotech, Inc. 2017-09-29
NCT01077232 Documentation of Humira in Psoriasis Patients in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT01077232 Completed AbbVie 2019-06-30
NCT01077128 Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab https://ClinicalTrials.gov/show/NCT01077128 Completed AbbVie 2012-09-30
NCT01076192 Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE) https://ClinicalTrials.gov/show/NCT01076192 Completed AbbVie 2014-09-30
NCT01052467 Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel) https://ClinicalTrials.gov/show/NCT01052467 Completed LEO Pharma 2010-05-31
NCT01019200 Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis https://ClinicalTrials.gov/show/NCT01019200 Completed George Washington University 2016-03-31
NCT00998829 Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis https://ClinicalTrials.gov/show/NCT00998829 Completed Pfizer 2012-05-31
NCT00930592 Peds Metabolic Syndrome in Psoriasis https://ClinicalTrials.gov/show/NCT00930592 Completed Tufts Medical Center 2012-07-31
NCT00930384 A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis https://ClinicalTrials.gov/show/NCT00930384 Completed George Washington University 2016-04-30
NCT00895375 Prevalence of Sleep Disturbances in Psoriasis https://ClinicalTrials.gov/show/NCT00895375 Completed Wake Forest University Health Sciences 2011-02-28
NCT00894777 Study Evaluating Management of Patients With Moderate and Severe Psoriasis https://ClinicalTrials.gov/show/NCT00894777 Completed Wyeth is now a wholly owned subsidiary of Pfizer 2009-11-30
NCT00893126 Premature Coronary Artery Disease (CAD) in Severe Psoriasis https://ClinicalTrials.gov/show/NCT00893126 Completed University of Michigan 2016-03-31
NCT00879944 Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index https://ClinicalTrials.gov/show/NCT00879944 Completed Northwestern University 2012-06-30
NCT00830817 Double-Blind Study of Topical WBI-1001 Cream on Patients With Psoriasis https://ClinicalTrials.gov/show/NCT00830817 Completed Welichem Biotech Inc. 2008-04-30
NCT00823914 Developing A Validated Measure of the Impact of Psoriasis on Chronic Quality of Life https://ClinicalTrials.gov/show/NCT00823914 Completed Massachusetts General Hospital 2013-12-31
NCT04149587 A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen https://ClinicalTrials.gov/show/NCT04149587 Recruiting Bausch Health Americas, Inc. 2022-03-30
NCT03149900 Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients https://ClinicalTrials.gov/show/NCT03149900 Completed University of Luebeck 2019-07-25
NCT03059953 A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The ‘APRAISAL’ Study) https://ClinicalTrials.gov/show/NCT03059953 Completed Genesis Pharma S.A. 2018-04-06
NCT03097003 A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium https://ClinicalTrials.gov/show/NCT03097003 Completed Amgen 2018-12-20
NCT02457000 Sleep, Circadian Rhythm & Skin Health https://ClinicalTrials.gov/show/NCT02457000 Active, not recruiting University Hospitals Cleveland Medical Center 2020-12-31
NCT03125655 Regulation of Inflammatory Genes in Psoriasis https://ClinicalTrials.gov/show/NCT03125655 Recruiting University of Alabama at Birmingham 2021-04-10
NCT00779675 Assessment of Long-Term Infliximab for Psoriasis (P05319) https://ClinicalTrials.gov/show/NCT00779675 Completed Merck Sharp & Dohme Corp. 2011-10-31
NCT00760669 An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants https://ClinicalTrials.gov/show/NCT00760669 Completed Janssen Korea, Ltd., Korea 2011-04-30
NCT00749398 Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047) https://ClinicalTrials.gov/show/NCT00749398 Completed Merck Sharp & Dohme Corp. 2010-09-30
NCT00727298 Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) https://ClinicalTrials.gov/show/NCT00727298 Completed Merck Sharp & Dohme Corp. 2011-08-31
NCT00725452 Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900) https://ClinicalTrials.gov/show/NCT00725452 Completed Merck Sharp & Dohme Corp. 2010-06-30
NCT00708708 Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings https://ClinicalTrials.gov/show/NCT00708708 Completed Pfizer 2013-12-31
NCT00710489 Potential Research Study Participant Registry https://ClinicalTrials.gov/show/NCT00710489 Completed University of California, Davis 2018-09-05
NCT00658827 Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis https://ClinicalTrials.gov/show/NCT00658827 Completed Janssen Biotech, Inc. 2016-09-30
NCT00602823 Genomic Study for the Prediction of Efficacy and Adverse Effects of CD11a Monoclonal Antibodies(Raptiva) https://ClinicalTrials.gov/show/NCT00602823 Completed National Taiwan University Hospital NA
NCT00555178 Regulatory T Cells (Tregs) in Polymorphic Light Eruption https://ClinicalTrials.gov/show/NCT00555178 Completed Medical University of Graz 2014-12-31
NCT00799877 Chronic Plaque Psoriasis (Ps) Registry https://ClinicalTrials.gov/show/NCT00799877 Active, not recruiting AbbVie 2022-09-15
NCT00451243 Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment https://ClinicalTrials.gov/show/NCT00451243 Completed National Taiwan University Hospital NA
NCT00437216 Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis https://ClinicalTrials.gov/show/NCT00437216 Completed Galderma Laboratories, L.P. 2006-07-31
NCT00407979 Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis https://ClinicalTrials.gov/show/NCT00407979 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2009-02-28
NCT00371163 Molecular and Cellular Characterization of Spongiotic Dermatitis https://ClinicalTrials.gov/show/NCT00371163 Completed University of California, Davis 2012-12-31
NCT00368784 T Cell Repertoire Analysis of Immune Mediated Skin Diseases https://ClinicalTrials.gov/show/NCT00368784 Recruiting University of California, Davis 2021-10-31
NCT00371774 Amevive Wisdom Acquired From Real-Time Evidence (A.W.A.R.Eâ„¢) Program https://ClinicalTrials.gov/show/NCT00371774 Completed Astellas Pharma Inc 2008-05-31
NCT00341809 Genetic Analysis of Psoriasis and Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00341809 Completed National Institutes of Health Clinical Center (CC) NA
NCT00293722 Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists https://ClinicalTrials.gov/show/NCT00293722 Completed Pfizer 2013-02-28
NCT00293709 Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Dermatologists https://ClinicalTrials.gov/show/NCT00293709 Completed Pfizer 2013-02-28
NCT00261976 A Long-term Safety Study of Infliximab (Remicade) https://ClinicalTrials.gov/show/NCT00261976 Completed Centocor, Inc. 2012-03-31
NCT00227240 Study Evaluating Enbrel (Etanercept) in Adult Patients With Plaque Psoriasis https://ClinicalTrials.gov/show/NCT00227240 Completed Pfizer 2009-06-30
NCT00167752 Psychiatric Problems in Chronic Skin Diseases https://ClinicalTrials.gov/show/NCT00167752 Completed University of Wisconsin, Madison 2006-02-28
NCT00162825 Role of CD7 in Skin Inflammation and Psoriasis https://ClinicalTrials.gov/show/NCT00162825 Completed National Taiwan University Hospital NA
NCT00131066 Long-Term Follow-Up Study of Psoriasis Patients https://ClinicalTrials.gov/show/NCT00131066 Completed MedImmune LLC 2003-10-31
NCT00097240 An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW) https://ClinicalTrials.gov/show/NCT00097240 Completed Genentech, Inc. NA
NCT00096928 A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) https://ClinicalTrials.gov/show/NCT00096928 Completed Genentech, Inc. NA
NCT00005781 Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles https://ClinicalTrials.gov/show/NCT00005781 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001371 A Pilot Study of Topical Antiflammin-2 for Psoriasis https://ClinicalTrials.gov/show/NCT00001371 Completed National Institutes of Health Clinical Center (CC) NA
NCT00026741 Research in Skin Inflammation https://ClinicalTrials.gov/show/NCT00026741 Completed National Institutes of Health Clinical Center (CC) NA
NCT00303186 Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy https://ClinicalTrials.gov/show/NCT00303186 Completed Pfizer 2011-06-30
NCT00098189 Follow-Up Study of Patients Previously Treated With Pimecrolimus Tablets for Chronic Plaque-Type Psoriasis https://ClinicalTrials.gov/show/NCT00098189 Completed Novartis NA
NCT00005660 The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases https://ClinicalTrials.gov/show/NCT00005660 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001420 Study of Psoriatic Arthritis https://ClinicalTrials.gov/show/NCT00001420 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03661866 A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for IMISC https://ClinicalTrials.gov/show/NCT03661866 Recruiting Target PharmaSolutions, Inc. 2026-10-31
NCT03374527 Recirculating Memory T Cells in the Pathogenesis of Psoriatic Arthritis and Cutaneous Psoriasis https://ClinicalTrials.gov/show/NCT03374527 Completed Istituto Ortopedico Galeazzi 2018-01-30
NCT03324919 Patient Centered Care Situation and Health-related Quality of Life by Patients With Psoriasis, Urticaria or Lupus https://ClinicalTrials.gov/show/NCT03324919 Completed University Hospital Regensburg 2017-04-30
NCT03254667 LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis https://ClinicalTrials.gov/show/NCT03254667 Enrolling by invitation Bausch Health Americas, Inc. 2030-11-10
NCT03253666 Nurses’ Health Study and Health Professionals Follow-Up Study (Dermatological Component) https://ClinicalTrials.gov/show/NCT03253666 Enrolling by invitation Harvard School of Public Health 2020-12-31
NCT02786186 A Registry of Patients With Moderate to Severe Plaque Psoriasis https://ClinicalTrials.gov/show/NCT02786186 Recruiting Novartis 2025-12-30
NCT02775500 Apremilast Pregnancy Exposure Registry https://ClinicalTrials.gov/show/NCT02775500 Recruiting University of California, San Diego 2022-02-28
NCT02707341 The Corrona Psoriasis (PSO) Registry https://ClinicalTrials.gov/show/NCT02707341 Enrolling by invitation Corrona, LLC. 2100-12-31
NCT02103361 Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project https://ClinicalTrials.gov/show/NCT02103361 Recruiting University of California, San Diego 2024-12-31
NCT02075697 Spanish Registry of Systemic Treatments in Psoriasis https://ClinicalTrials.gov/show/NCT02075697 Recruiting Fundación Academia Española de Dermatología 2025-10-31
NCT02045485 P Wave and QT Dispersion in Psoriasis https://ClinicalTrials.gov/show/NCT02045485 Completed Yuzuncu Yıl University 2006-06-30
NCT01848028 PsoBest - The German Psoriasis Registry https://ClinicalTrials.gov/show/NCT01848028 Recruiting Universitätsklinikum Hamburg-Eppendorf 2025-12-31
NCT04359628 How Does Patients’ Overall Assessment of Their Health Vary Across and Within Different Disease Groups? https://ClinicalTrials.gov/show/NCT04359628 Recruiting Vastra Gotaland Region 2020-09-30
NCT03475914 Characterization of Cutaneous Microbiota in the Psoriasis Pathogenesis https://ClinicalTrials.gov/show/NCT03475914 Completed Istituto Ortopedico Galeazzi 2017-06-29
NCT02719314 Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis https://ClinicalTrials.gov/show/NCT02719314 Recruiting Charite University, Berlin, Germany 2025-11-30
NCT00322439 Observational Safety Study of Etanercept (Enbrel) for Treatment of Psoriasis https://ClinicalTrials.gov/show/NCT00322439 Completed Amgen 2012-12-11